A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer

Journal of Urology

Volumn 178, Issue 6, 2007, Pages 2378-2384

  Morris, Michael J ^a   Kelly, W Kevin ^a   Slovin, Susan ^a   Ryan, Charles ^a   Eicher, Caitlin ^a   Heller, Glenn ^a   Scher, Howard I ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bortezomib; interleukin 6; neoplasm metastasis; prostate; prostatic neoplasms

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; HEMOGLOBIN; INTERLEUKIN 6; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; THROMBOCYTOPENIA; URINARY FREQUENCY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORCHIECTOMY; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRAZINES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35948969806     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.015     Document Type: Article

References (20)

1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
2. Lou W., Ni Z., Dyer K., Tweardy D.J., and Gao A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42 (2000) 239
3. Giri D., Ozen M., and Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159 (2001) 2159
4. Garcia-Moreno C., Mendez-Davila C., de La Piedra C., Castro-Errecaborde N.A., and Traba M.L. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 50 (2002) 241
5. Borsellino N., Belldegrun A., and Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55 (1995) 4633
6. Lin D.L., Whitney M.C., Yao Z., and Keller E.T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7 (2001) 1773
7. Chen T., Wang L.H., and Farrar W.L. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60 (2000) 2132
8. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58 (1998) 4640
9. Papandreou C.N., Daliani D.D., Nix D., Yang H., Madden T., Wang X., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108
10. Beg A.A., and Baltimore D. An essential role for NF-kB in preventing TNF-α-induced cell death. Science 274 (1996) 782
11. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274 (1996) 784
12. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59 (1999) 2615
13. Aljada A., Ghanim H., Assian E., Mohanty P., Hamouda W., Garg R., et al. Increased IkappaB expression and diminished nuclear NF-kappaB in human mononuclear cells following hydrocortisone injection. J Clin Endocrinol Metab 84 (1999) 3386
14. Steer J.H., Kroeger K.M., Abraham L.J., and Joyce D.A. Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 275 (2000) 18432
15. Ray A., LaForge K.S., and Sehgal P.B. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10 (1990) 5736
16. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No. 48 (1979), World Health Organization, Geneva
17. Hamilton A.L., Eder J.P., Pavlick A.C., Clark J.W., Liebes L., Garcia-Carbonero R., et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23 (2005) 6107
18. Dy G.K., Thomas J.P., Wilding G., Bruzek L., Mandrekar S., Erlichman C., et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, Velcade), in patients with advanced cancer. Clin Cancer Res 11 (2005) 3410
19. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505
20. Dreicer R., Petrylak D., Agus D., Webb I., and Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13 (2007) 1208